-
Bioetech Insider Buying: ArQule Inc. (NASDAQ:ARQL), Akebia Therapeutics (NASDAQ:AKBA), Oragenics Inc. (NYSEMKT:OGEN), MediciNova Inc. (NASDAQ:MNOV), Cyclacel Pharmaceuticals (NASDAQ:CYCC)
ArQule Inc. (NASDAQ:ARQL) Director Susan L. Kelley acquired 50,000 shares of ArQule stock on the open market in a transaction that occurred on Thursday, November 13th. The stock was purchased at an average price of $1.20 per share, for a total transaction of $60,000.00. Following the completion of the acquisition, the director now directly owns…
-
Momentum Stocks: Alpha Natural Resources (NYSE:ANR), Liberty Global plc (NASDAQ:LBTYA), Limoneira Company (NASDAQ:LMNR), Plains All American Pipeline (NYSE:PAA), ArQule Inc. (NASDAQ:ARQL)
On 10 November Alpha Natural Resources, Inc. (NYSE:ANR) said it has idled an underground coal mine in southern West Virginia. Alpha Natural Resources, Inc. (NYSE:ANR) in last trading activity increased 0.38% to close at $2.61. Company weekly performance is -1.14% while its quarterly performance stands at -34.91%. Alpha Natural Resources, Inc. (NYSE:ANR) is -67.98% away…
-
Biotech Stocks in Bullish Zone: Celldex Therapeutics (NASDAQ:CLDX), Sunesis Pharmaceuticals (NASDAQ:SNSS), Amicus Therapeutics (NASDAQ:FOLD), Navidea Biopharmaceuticals (NYSEMKT:NAVB), ArQule (NASDAQ:ARQL)
Celldex Therapeutics, Inc. (NASDAQ:CLDX) on 14 November announced an interim update from the Phase 2 ReACT study of rindopepimut in EGFRvIII-positive glioblastoma (GBM). The ReACT results demonstrate clear signs of clinical activity in patients with recurrent glioblastoma, including groups both naive and refractory to bevacizumab (Avastin(R)). The data were presented in a platform presentation by…
-
Big Movers: Marvell Technology Group (NASDAQ:MRVL), ArQule Inc. (NASDAQ:ARQL), Dicerna Pharmaceuticals (NASDAQ:DRNA), The Laclede Group (NYSE:LG), Sucampo Pharmaceuticals (NASDAQ:SCMP)
Shares of Marvell Technology Group Ltd. (NASDAQ:MRVL) have received an average rating of “Buy” from the twenty-five brokerages that are presently covering the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to…
-
Active Stocks to Watch: ArQule Inc. (NASDAQ:ARQL), The Blackstone Group L.P. (NYSE:BX), Nordic American Tankers Limited (NYSE:NAT), Range Resources Corporation (NYSE:RRC), TWIN
ArQule Inc. (NASDAQ:ARQL) announced positive top-line results from a randomized, double-blind, placebo-controlled Phase 2 clinical trial of tivantinib as a single agent in metastatic prostate cancer. This trial (clinicaltrials.gov identifier NCT01519414) was conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s Cancer Therapy Evaluation Program (CTEP) (“A Randomized, Double-Blind, Placebo-Controlled…
-
Trending Stocks: ArQule Inc. (NASDAQ:ARQL), Nabors Industries (NYSE:NBR), Express Scripts Holding Company (NASDAQ:ESRX), Covisint Corporation (NASDAQ:COVS), Granite Construction Incorporated (NYSE:GVA)
ArQule Inc. (NASDAQ:ARQL) reported its results of operations for the fiscal quarter and nine months ended September 30, 2014. The Company reported a net loss of $6,399,000 or $0.10 per share for the quarter ended September 30, 2014, compared to a net loss of $6,083,000 or $0.10 per share for the quarter ended September 30,…
-
Biotech Gainers: Bio-Rad Laboratories (NYSE:BIO), Novavax (NASDAQ:NVAX), Celldex Therapeutics (NASDAQ:CLDX), Progenics Pharmaceuticals (NASDAQ:PGNX), ArQule Inc. (NASDAQ:ARQL)
Bio-Rad Laboratories Inc. (NYSE:BIO) agreed Monday to pay about $55 million to end a Justice Department investigation into whether it failed to prevent the bribery of government officials in Russia, Thailand and Vietnam, and falsified records to hide its payments. Bio-Rad Laboratories, Inc. (NYSE:BIO) in last trading activity moved up 0.41% to close at $111.05.…
-
Hot News: ArQule Inc. (NASDAQ:ARQL), ArcelorMittal SA (ADR) (NYSE:MT), Bruker Corporation (NASDAQ:BRKR), The Boeing Company (NYSE:BA), Methanex Corporation (NASDAQ:MEOH)
ArQule Inc. (NASDAQ:ARQL) announced that it will report its financial results for the third quarter of 2014 on Monday November 10 2014 at 7:00 a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern Time that day to discuss these results. ArQule Inc. (NASDAQ:ARQL) in last trading activity moved down -1.83%…
-
Biotech Firms Will be the Next Acquisition Targets or Partners for the Pharma Industry – (GILD, SRPT, ARNA, ARQL)
Biotech stocks across the globe are noticing their shares lifted by optimism that they will be the next acquisition targets or drug deal partners for a pharmaceutical industry under attack with patent expiries and clinical trial failures. But investors have been burnt many times prior to investing in small companies only for them to run…
-
Investors Now Paying More Attention to the anti-obesity Drug Market – (ARNA, ARQL, GILD, ILMN, CTIC, VVUS)
Shares of firms developing or marketing anti-obesity drugs, such as Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and VIVUS, Inc. (NASDAQ:VVUS) both edged up yesterday, have gathered more attention from investors this year as two weight loss drugs have successfully gained approval from the U.S. Food and Drug Administration, the first approvals in over 13 years. Roche Holdings…